Aktieanalys

Magle Chemoswed Q1: Expansion by acquisition - Redeye

Redeye Publicerad: 19 Apr 08:49

Redeye provides a research update following the Q1 report recently published by Magle. The first quarter of 2024 for Magle was primarily marked by the public offer to acquire Amniotics. We believe that Amniotics' cGMP-licensed facilities will be able to generate long-term added value for Magle. Beyond that, the company reported a lower sales figure than expected at SEK38.2m, a -1% y/y decrease, with reduced revenue from its DSM products. However, we reiterate our previous fair value range (SEK25 – SEK58) with a base case valuation of SEK40.

Länk till analysen i sin helhet: https://www.redeye.se/research/996205/magle-chemoswed-q1-expansion-by-acquisition?utm_source=finwire&utm_medium=RSS

Nyheter om Magle Chemoswed

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!